Exact Sciences deal adds $3 billion in incremental sales in 2026, CEO Ford says Nutrition sales fell 6%; diabetes and heart devices face competition, analysts note Middle East conflict causes minor ...

ABBOTT PARK, Ill., March 23, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has completed the acquisition of Exact Sciences, establishing Abbott as a leader in fast-growing cancer ...

Establishes Abbott as a leader in fast-growing cancer screening and diagnostics segments Advances Abbott's mission to make healthcare more accessible and give people more control over their health ...

MADISON, Wis. -- Abbott expects to close its acquisition of Exact Sciences on Monday, the healthcare giant said. Madison-based Exact Sciences is known for its cancer detection technology such as ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The deal brings Exact Sciences ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Abbott made one of the biggest deals in recent medtech history last week when it announced its plan to acquire Exact Sciences — maker of colon cancer screening test Cologuard — for $23 billion.

Abbott is getting into cancer testing with its $21 billion acquisition Exact Sciences, the maker of the game-changing colorectal cancer test Cologuard. Abbott markets well-known diagnostics for ...

It was Bloomberg that first reported rumors of the buyout on Wednesday, citing that talks were nearing fruition, according to people familiar with the matter. At the time of the article, Exact only ...

Abbott announced on Thursday, Nov. 20 it plans to buy Exact Sciences, a Madison-based maker of cancer screening and diagnostic tests, in a deal valued at an estimated $23 billion, including debt. The ...

Abbot Laboratory has announced a deal to acquire Madison-based Exact Sciences for approximately $21 billion. Exact Sciences, known for its Cologuard cancer screening test, was founded in 1995 and ...

Abbott to buy Exact Sciences in $23 billion deal Exact's flagship colorectal cancer test to join Abbott's portfolio Abbott eyes international expansion for Exact's tests Aims for broad reimbursement ...